

## Wednesday, February 4

	Main Auditorium	Auditorium 3	Auditorium 2	Madrid Room	
9.00					9.00
9.30	<b>MTC1</b> From infection to diseases at different anatomic sites	<b>OC1</b> HPV testing 1	<b>JE1</b> Curso de colposcopia		9.30
10.30	Coffee Break			<b>W1</b> WACC Forum	10.00
11.00	<b>MTC2</b> New strategies & innovations in cervical cancer control	<b>OC2</b> Epidemiology & natural history 1	<b>JE2</b> Verrugas genitales Cribado/ Consenso	Anti-vaccine movements: tactics and solutions	
12.45					13.00
13.00	<b>Symposium BD</b>				
14.15					14.15
14.30	<b>MTC3</b> Management of HPV cervical diseases - the state of the art	<b>OC3</b> Vaccine 1 Impact	<b>JE3</b> Equidad asistencial: de la oncología a la clínica	<b>W2</b> Patient survivors' voices: what they want	14.30
16.00	Coffee Break				16.00
16.30	<b>MTC4</b> HPV-associated diseases in non-cervical sites - what the clinician should know	<b>OC4</b> Vaccine 2 Effectiveness	<b>JE4</b> Técnica quirúrgica en el cáncer de cuello uterino	<b>OC5</b> WACC	16.30
17.00			<b>JE5</b> La educación en el médico de cabecera en el VPH		17.00
18.00					18.00
18.30					18.30
19.00					19.00
20.00	<b>Welcome Reception (in Sevilla downtown at the Real Alcázar)</b>				20.00

## Thursday, February 5

	Main Auditorium	Auditorium 3	Auditorium 2	Madrid Room	Bruselas Room	
8.15						8.15
8.30	<b>MSS1</b> How to introduce HPV testing into primary screening	<b>OC6</b> Vaccine 3 New developments	<b>CS1</b> Clinical advances & modern management of vulvar carcinoma	<b>OC7</b> H&N 1	<b>HN</b> Colposcopy Course (Separate registration required)	8.30
9.45	<b>MSS2</b> Surveillance and impact of HPV prophylactic vaccines in population: current picture		<b>CS2</b> HPV infection & precancers of the vulva	<b>OC8</b> H&N 2		HN
10.00						10.00
11.30	Coffee Break					11.30
12.00	<b>Symposium SPMSD</b>					12.00
13.15						13.15
13.30		<b>Symposium ABBOTT</b>		<b>Symposium INCELL</b>		13.30
14.45	<b>MSS3</b> Funding cervical cancer control	<b>SS1</b> Immunotherapy of HPV associated diseases	<b>CS3</b> ADC in situ and invasive adenocarcinoma	<b>OC10</b> HPV testing 2		14.45
16.00	Coffee Break					16.00
16.15						16.15
16.30	<b>MSS4</b> Methods of triage of HPV+ women	<b>SS2</b> New challenges facing HPV 16 & 18 infection	<b>CS4</b> The new face of colposcopy at the age of technical progress	<b>OC11</b> Epidemiology & natural history 2		16.30
16.40						16.40
18.00			<b>OC9</b> Colposcopy - Management			18.00
19.30						19.30

**HN** Head & Neck Session

## Friday, February 6

	Auditorium 3	Auditorium 2	Madrid Room	Bruselas Room	Paris E Room	
8.15						8.15
8.30	<b>MSS5</b> HPV-based screening implementation	<b>HN1</b> HPV driven oropharyngeal cancer	<b>HN</b> <b>SS3</b> FIGO session	<b>CS5</b> Clinical decision-making for cervical diseases	<b>SS6</b> Health economical modelling	8.30
9.45	<b>MSS6</b> Roadmap	↩ Roadmap (Auditorium 3)	<b>SS4</b> Italian session	<b>SS5</b> Spanish session (in English)	<b>SS7</b> Screening strategies at the extremes	9.45
10.00						10.00
11.30	Coffee Break					11.30
11.45	<b>Main Auditorium Symposium GSK</b>					11.45
12.00						12.00
13.15		<b>Symposium HOLOGIC</b>				13.15
13.30						13.30
14.45	<b>MSS7</b> New insights in cervical cancer control	<b>HN2</b> The HPV value for , detection control & management of OPC	<b>HN</b> <b>SS8</b> Cancers associated with HPV: the current picture	<b>SS10</b> HPV latency	<b>CS6</b> HPV infection: the state of the art	14.45
16.30	Coffee Break					16.30
16.45						16.45
17.00	<b>MSS8</b> Potential impact of the quadrivalent, bivalent and nonavalent HPV vaccines, and alternative HPV vaccination strategies	<b>HN3</b> Decision-making in management of OPC	<b>HN</b> <b>SS9</b> Self-sampling	<b>SS11</b> Immunology	<b>CS7</b> Anogenital HPV infection in men	17.00
18.15		<b>HN4</b> Controversies & key questions	<b>HN</b> <b>Symposium GENOMICA</b>	<b>SS12</b> The biology of HPV		18.15
19.30						19.30

**HN** Head & Neck Session

## Saturday, February 7

	Auditorium 3	Auditorium 2	Madrid Room	Bruselas Room	
8.00					8.00
8.15			<b>SS14</b> CoHeaHr		8.15
8.30	<b>MSS9</b> HPV vaccines: unexpected findings	<b>OC12</b> Screening		<b>OC15</b> Anal neoplasia	8.30
10.00	<b>MSS10</b> Novel approaches of HPV and non HPV-based cervical cancer screening	<b>OC13</b> HPV screening	<b>SS15</b> Prevention of CC in Central, Eastern Europe & Central Asia	<b>OC16</b> Vulvar, vaginal and other neoplasia	10.00
11.30	<b>SS13</b> HPV quality control	<b>OC14</b> Self-sampling	<b>SS16</b> Cervical cancer prevention in low income countries	<b>OC17</b> Molecular markers	11.30
12.00					12.00
13.00					13.00
13.15					13.15